A Phase 1 Study of DCC-3009 in People With Advanced Gastrointestinal Stromal Tumors

Full Title

Purpose

Researchers want to find the best dose of DCC-3009 to use in people with gastrointestinal stromal tumors (GIST). The people in this study have GIST that has metastasized (spread) after treatment. In addition, their cancers have a mutation (change) in the KIT or PDGFRA gene. These mutations are common in people with GIST and can cause cancer to grow.

DCC-3009 blocks enzymes that help cancer cells to survive and grow. By blocking these enzymes, DCC-3009 may help slow or stop the growth of your cancer. It is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

• Have GIST that has metastasized after treatment and has a KIT or PDGFRA mutation.
• Have recovered from the serious side effects of prior therapies before taking DCC-3009.
• Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Ping Chi’s office at 646-888-4166.